| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| rilapladib | phospholipase a2 | NA | Successful target | TTD , DGIDB | Atherosclerosis[MeSHID:D050197] Cardiovascular Diseases[MeSHID:D002318] Arteriosclerosis[MeSHID:D001161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.96 | phase 1 | unknown |
| rilapladib | platelet-activating factor acetylhydrolase | small molecule | Clinical trial target | TTD , drugbank , DGIDB | Atherosclerosis[MeSHID:D050197] Cardiovascular Diseases[MeSHID:D002318] Arteriosclerosis[MeSHID:D001161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
21.22 | investigational,phase 1 | inhibitor |
| rilapladib | platelet-activating factor acetylhydrolase | small molecule | Clinical trial target | TTD , drugbank , DGIDB | Atherosclerosis[MeSHID:D050197] Cardiovascular Diseases[MeSHID:D002318] Arteriosclerosis[MeSHID:D001161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
21.22 | investigational,phase 1 | unknown |
| rilapladib | thymidine kinase 1 | NA | Successful target | TTD , DGIDB | Atherosclerosis[MeSHID:D050197] Cardiovascular Diseases[MeSHID:D002318] Arteriosclerosis[MeSHID:D001161] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.54 | phase 1 | unknown |
| click here to return to the previous page | ||||||||